Biotech Co.* |
Pharma Co. |
Product | Terms/Details (Date) |
Cleveland |
SynCo Bio Partners BV (the Netherlands) |
Deal for the manufacturing of CBLI's Protectan CBLB502 product |
SynCo will manufacture the radioprotection agent under undisclosed terms (10/24) |
Cytogen Corp. |
Laureate Pharma Inc. |
They renewed deal for the manufacture of Cytogen's ProstaScint |
The monoclonal antibody immunoconjugate is used for prostate cancer imaging; terms of the deal were not disclosed (10/25) |
Debiopharm |
Four companies |
Four companies got territory-specific rights to market Debiopharm's Sanvar for treating acute esophageal variceal bleeding |
Rights were licensed to Ranbaxy Laborator-tories in India, Bangladesh and Nepal; EMS Sigma Farma in Brazil; Tzamal Bio-Pharma Ltd. in Israel; and LG Life Sciences in Korea (10/23) |
Genentech Inc. |
Lonza Group Ltd. (Switzerland) |
Lonza is purchasing Genentech's manufacturing facility in Porrino, Spain, for $150M |
Lonza will manufacture certain Genentech products at its facility being constructed in Singapore; Genentech has an option to acquire the Singapore facility for $290M, plus up to $70M in milestone payments (11/8) |
Gilead |
Bristol-Myers Squibb Co. |
Deal to commercialize their combination HIV product Atripla in Canada |
The effort, pending approval in Canada, expands their agreement covering the U.S.; costs and profits will be shared (9/28) |
Millennium |
Ortho Biotech Inc. (unit of Johnson & Johnson) |
Two-year deal under which Ortho will help promote Velcade in the U.S. |
Velcade is approved for treating multiple myeloma; Ortho will get payments for its sales force, and a commission on sales that exceed certain targets (10/26) |
TopoTarget |
Movianto Deutschland GmbH (Germany) |
Deal under which Movianto will distribute TopoTarget's newly launched product Savene |
The product is used as an antidote to chemotherapy accidents; terms of the deal were not disclosed (10/5) |
Viron |
Diosynth Biotechnology (unit of NV Organon) |
Deal for the manufacture of Viron's lead molecule, VT-111 |
The cardiovascular product is in Phase II trials; terms of the deal were not disclosed (10/24) |
| Notes: | |||
| # The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
| * Private companies are indicated with an asterisk. | |||
| Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
| CSE = Copenhagen Stock Exchange; NYSE = New York Stock Exchange. | |||
To read more on related topics, click on one of the words below.